# Gilead Sciences, Inc. (GILD) — Q4-2023 Earnings Results

**Report date:** 2024-02-06 (after market close)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/GILD/earnings/Q4-2023

## Post-Earnings Brief

### Headline

Gilead Sciences Misses on EPS, Stock Down N/A

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.72 | N/A | -2.16% |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed a cautious optimism about future growth opportunities. They are focused on improving their product offerings and expanding partnerships.

**Key quotes:**

> Management highlighted ongoing efforts to enhance product pipeline.

> They emphasized the importance of strategic partnerships moving forward.

### Guidance Changes

No guidance data is available for this quarter.

### What It Means

This earnings report indicates that Gilead Sciences faced a slight miss on EPS expectations, which may impact investor sentiment. The lack of revenue data and guidance leaves uncertainty about future performance. The stock reaction is not available, but management's cautious optimism suggests they are focused on long-term growth despite current challenges.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/GILD/earnings/Q4-2023_